Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
LAVA Therapeutics N.V. - Ordinary Shares
(NQ:
LVTX
)
1.740
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about LAVA Therapeutics N.V. - Ordinary Shares
< Previous
1
2
Next >
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
November 21, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via
GlobeNewswire
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 02, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
August 04, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
August 04, 2025
From
Halper Sadeh LLC
Via
Business Wire
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
August 04, 2025
XOMA Royalty adds milestone and royalty economics associated with two partnered assets
From
XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
June 10, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
March 05, 2024
Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
January 29, 2024
Via
AB Newswire
Topics
Retirement
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
January 25, 2024
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 16, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
August 22, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
August 14, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway
June 14, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
June 08, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
June 01, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
May 30, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
April 11, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
March 09, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
February 16, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
February 09, 2023
From
LAVA Therapeutics N.V.
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
